CY1115658T1 - Νεος βακιλοϊικος φορεας - Google Patents
Νεος βακιλοϊικος φορεαςInfo
- Publication number
- CY1115658T1 CY1115658T1 CY20141100865T CY141100865T CY1115658T1 CY 1115658 T1 CY1115658 T1 CY 1115658T1 CY 20141100865 T CY20141100865 T CY 20141100865T CY 141100865 T CY141100865 T CY 141100865T CY 1115658 T1 CY1115658 T1 CY 1115658T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bakilic
- new
- recombinant
- recombinant baculovirus
- medicaments
- Prior art date
Links
- 241000701447 unidentified baculovirus Species 0.000 abstract 2
- 108700005077 Viral Genes Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
- C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ανασυνδυασμένος φορέας μεταφοράς ικανός έκφρασης ξένου γονιδίου συντηγμένου προς ιικό γονίδιο υπό τον έλεγχο ενός διπλού υποκινητή και ανασυνδυασμένου βακιλοϊού και μέθοδοι για παραγωγή αυτού, καθώς επίσης φαρμακευτικές ουσίες που περιλαμβάνουν τον ανασυνδυασμένο βακιλοϊό ως δραστικό συστατικό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006032863 | 2006-02-09 | ||
EP20100193968 EP2363463B1 (en) | 2006-02-09 | 2007-02-08 | Novel baculoviral vector |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115658T1 true CY1115658T1 (el) | 2017-01-25 |
Family
ID=38345218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100865T CY1115658T1 (el) | 2006-02-09 | 2014-10-22 | Νεος βακιλοϊικος φορεας |
Country Status (24)
Country | Link |
---|---|
US (1) | US9023365B2 (el) |
EP (3) | EP2363463B1 (el) |
JP (1) | JP4171930B2 (el) |
KR (1) | KR101472924B1 (el) |
CN (2) | CN101384714A (el) |
AP (1) | AP2880A (el) |
AR (1) | AR059422A1 (el) |
AU (1) | AU2007213030B2 (el) |
BR (1) | BRPI0707646A2 (el) |
CA (1) | CA2636632C (el) |
CY (1) | CY1115658T1 (el) |
DK (2) | DK2363462T3 (el) |
ES (1) | ES2520968T3 (el) |
IL (3) | IL192681A (el) |
MX (1) | MX2008010299A (el) |
MY (1) | MY144455A (el) |
NO (1) | NO20083376L (el) |
PL (1) | PL2363463T3 (el) |
PT (1) | PT2363463E (el) |
RU (2) | RU2453603C2 (el) |
SI (1) | SI2363463T1 (el) |
TW (1) | TWI477602B (el) |
WO (1) | WO2007091624A1 (el) |
ZA (1) | ZA200806144B (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
MY155412A (en) * | 2007-08-07 | 2015-10-15 | Educational Foundation Jichi Medical Univ | Baculoviral vectors with a dual vertebrate and baculovirus promoter controlling an immunogenic fusion gene |
JP5607620B2 (ja) | 2008-07-25 | 2014-10-15 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | 抗a型インフルエンザウイルス中和抗体およびその使用 |
US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
US20110201086A1 (en) | 2010-02-12 | 2011-08-18 | Otsuka Pharmaceutical Co., Ltd. | Method for producing recombinant virus |
CN102234646B (zh) * | 2010-04-23 | 2014-10-22 | 深圳华大基因科技有限公司 | 一种启动子SbUbi1、其制备方法及用途 |
JP2013540700A (ja) | 2010-08-09 | 2013-11-07 | サイバツクス・インコーポレイテツド | 病気を予防するための方法および組成物 |
MX352338B (es) | 2011-07-18 | 2017-11-17 | Inst Res Biomedicine | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. |
CN104735977B (zh) * | 2012-06-12 | 2016-09-21 | 替代基因表达公司 | 用于在宿主细胞中表达重组蛋白的杆状病毒dna元件 |
JPWO2016059911A1 (ja) * | 2014-10-17 | 2017-07-27 | 国立大学法人金沢大学 | マラリアワクチン |
CL2014003146A1 (es) * | 2014-11-20 | 2015-06-12 | Univ Santiago Chile | Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus. |
MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
RU2626590C2 (ru) * | 2015-12-18 | 2017-07-28 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Генетическая конструкция для экспрессии генов в клетках насекомого polypedilum vanderplanki |
CN105779499B (zh) * | 2016-03-23 | 2019-11-19 | 江苏科技大学 | 重组杆状病毒和其应用及构建该重组杆状病毒的载体 |
CN110484657A (zh) * | 2019-09-06 | 2019-11-22 | 广东省农业科学院植物保护研究所 | 检测斜纹夜蛾成虫带核型多角体病毒的巢式pcr引物、试剂盒及其方法 |
WO2023157880A1 (ja) * | 2022-02-18 | 2023-08-24 | 国立大学法人金沢大学 | マラリアワクチン及びマラリア予防・治療方法 |
CN117305365B (zh) * | 2023-11-28 | 2024-03-19 | 中国科学院生物物理研究所 | 昆虫细胞—哺乳动物细胞表达穿梭载体SmartBM-1及其应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
AU629554B2 (en) | 1988-06-24 | 1992-10-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Exogenous gene expression vector containing chick beta-actin gene promoter |
US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
US6485729B1 (en) | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
US5976552A (en) | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
JP3090586B2 (ja) | 1994-03-15 | 2000-09-25 | 片倉工業株式会社 | システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法 |
GB9406492D0 (en) | 1994-03-31 | 1994-05-25 | Isis Innovation | Malaria peptides |
US6183993B1 (en) | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
KR20000036051A (ko) | 1996-09-11 | 2000-06-26 | 마빈 씨. 구트리 | 변형 외피 단백질을 보유하는 비포유류 dna 바이러스를 이용한 포유류 세포에서의 외래 유전자 발현 |
AU7126998A (en) | 1997-04-16 | 1998-11-11 | Connaught Laboratories Inc. | Anti-influenza compositions supplemented with neuraminidase |
GB9711578D0 (en) | 1997-06-04 | 1997-07-30 | Oxford Biomedica Ltd | Novel retroviral vector production systems |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
US20030125278A1 (en) | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
DE19735593C2 (de) | 1997-08-15 | 1999-08-26 | Hepavec Ag Fuer Gentherapie | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
JP2003530305A (ja) | 1999-05-03 | 2003-10-14 | ザ ユーエイビー リサーチ ファンデーション | 非侵襲的遺伝子免疫、それによる発現産物、およびそれらの使用 |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
JP2003501042A (ja) | 1999-05-27 | 2003-01-14 | ジェノボ, インコーポレイテッド | 非哺乳動物ウイルス由来のキャリアベクターを使用する、組換えウイルスの産生のための組成物および方法 |
US6589783B2 (en) * | 2000-04-13 | 2003-07-08 | Novagen, Inc. | Multiple host expression vector |
US6607912B2 (en) | 2000-08-11 | 2003-08-19 | Boyce Thompson Institute For Plant Research, Inc. | GP64-null baculoviruses pseudotyped with heterologous envelope proteins |
JP2002235236A (ja) | 2000-12-05 | 2002-08-23 | Kuraray Co Ltd | ポリビニルアルコール系水溶性繊維 |
US20040071733A1 (en) | 2001-02-05 | 2004-04-15 | Hiroshi Takaku | Baculovirus vector vaccine |
JP4655388B2 (ja) | 2001-03-05 | 2011-03-23 | 富士レビオ株式会社 | タンパク質の生産方法 |
US20030104965A1 (en) | 2001-08-14 | 2003-06-05 | Lonza Inc. | Laundry sanitizer containing partially halogenated hydantoins |
GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
WO2003020322A1 (de) | 2001-09-04 | 2003-03-13 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Vektor zur induktion einer immunantwort |
JP2003284557A (ja) | 2002-03-25 | 2003-10-07 | Alarvita Biolife Corp | 新規バクロウィルス移入ベクターおよび外来遺伝子発現用の組換えバクロウィルス |
AU2003266628A1 (en) | 2002-09-25 | 2004-04-19 | Osaka Industrial Promotion Organization | Baculovirus vector, method of constructing baculovirus vector and gene transfer method |
US7416890B2 (en) | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
JP2005015346A (ja) | 2003-06-23 | 2005-01-20 | Hiroshi Takaku | バキュロウイルス含有抗ウイルス剤 |
WO2005040388A2 (en) | 2003-08-22 | 2005-05-06 | Nucleonics Inc. | Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments |
US7527967B2 (en) * | 2003-11-25 | 2009-05-05 | Academia Sinica | Recombinant baculovirus and virus-like particle |
GB0425739D0 (en) | 2004-11-23 | 2004-12-22 | Procure Therapeutics Ltd | Humanised baculovirus 2 |
US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
JP2009001493A (ja) | 2005-09-27 | 2009-01-08 | Nationa Hospital Organization | Dnaワクチン組成物 |
DE602006015985D1 (de) * | 2005-09-30 | 2010-09-16 | Philadelphia Health & Educatio | Antigene gegen das leberstadium von plasmodium |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
-
2007
- 2007-02-07 TW TW096104446A patent/TWI477602B/zh not_active IP Right Cessation
- 2007-02-08 MX MX2008010299A patent/MX2008010299A/es active IP Right Grant
- 2007-02-08 US US12/278,916 patent/US9023365B2/en not_active Expired - Fee Related
- 2007-02-08 WO PCT/JP2007/052195 patent/WO2007091624A1/ja active Application Filing
- 2007-02-08 BR BRPI0707646-0A patent/BRPI0707646A2/pt not_active IP Right Cessation
- 2007-02-08 ZA ZA200806144A patent/ZA200806144B/xx unknown
- 2007-02-08 CN CNA2007800051618A patent/CN101384714A/zh active Pending
- 2007-02-08 RU RU2008136204/10A patent/RU2453603C2/ru not_active IP Right Cessation
- 2007-02-08 MY MYPI20082690 patent/MY144455A/en unknown
- 2007-02-08 PL PL10193968T patent/PL2363463T3/pl unknown
- 2007-02-08 EP EP20100193968 patent/EP2363463B1/en active Active
- 2007-02-08 SI SI200731561T patent/SI2363463T1/sl unknown
- 2007-02-08 CA CA2636632A patent/CA2636632C/en not_active Expired - Fee Related
- 2007-02-08 AU AU2007213030A patent/AU2007213030B2/en not_active Ceased
- 2007-02-08 DK DK10193966T patent/DK2363462T3/da active
- 2007-02-08 CN CN2013100885284A patent/CN103394096A/zh active Pending
- 2007-02-08 JP JP2007531528A patent/JP4171930B2/ja not_active Expired - Fee Related
- 2007-02-08 DK DK10193968T patent/DK2363463T3/da active
- 2007-02-08 AP AP2008004576A patent/AP2880A/xx active
- 2007-02-08 PT PT10193968T patent/PT2363463E/pt unknown
- 2007-02-08 EP EP07708219A patent/EP1983047A4/en not_active Withdrawn
- 2007-02-08 ES ES10193968.4T patent/ES2520968T3/es active Active
- 2007-02-08 EP EP20100193966 patent/EP2363462B1/en active Active
- 2007-02-09 AR ARP070100552A patent/AR059422A1/es unknown
-
2008
- 2008-07-08 IL IL19268108A patent/IL192681A/en not_active IP Right Cessation
- 2008-08-04 NO NO20083376A patent/NO20083376L/no not_active Application Discontinuation
- 2008-08-26 KR KR1020087020913A patent/KR101472924B1/ko not_active IP Right Cessation
-
2011
- 2011-01-19 IL IL210742A patent/IL210742A/en not_active IP Right Cessation
- 2011-01-19 IL IL210740A patent/IL210740A/en not_active IP Right Cessation
-
2012
- 2012-03-02 RU RU2012108128/10A patent/RU2012108128A/ru not_active Application Discontinuation
-
2014
- 2014-10-22 CY CY20141100865T patent/CY1115658T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115658T1 (el) | Νεος βακιλοϊικος φορεας | |
CR20110221A (es) | Terapia de combinación con péptidos epoxicetonas peptídicas | |
CY1120426T1 (el) | Πολυπεπτιδιο ace2 | |
CY1121618T1 (el) | Επεκτεινομενα διαλυτα ρη20 πολυπεπτιδια και χρησεις αυτων | |
CR20120345A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
PH12016500606A1 (en) | Insulin preparations containing methionine | |
SV2010003704A (es) | Polipeptidos modificados del factor ix y usos de los mismos | |
MX2017001881A (es) | Farmaco de afinidad encapsulado en liposoma. | |
FR2936247B1 (fr) | Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire. | |
UY35703A (es) | Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos | |
BR112012017345A2 (pt) | "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)" | |
BRPI0816128A2 (pt) | Uso de uma composição de estabilização, composição de estabilização, produto de cuidado corporal, e, produto doméstico. | |
TW200806317A (en) | Methods for reducing protein aggregation | |
ES2722799T3 (es) | Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13 | |
MX2018004852A (es) | Proteinas mirac. | |
MY169703A (en) | Antimicrobial fusion compounds and uses thereof | |
MX2011006301A (es) | Produccion de alcoholes de cadena ramificada por medio de microorganismos fotosinteticos. | |
WO2006079790A3 (en) | Controlled production and delivery of biologically active agents by gut bacteria | |
EP2179035B8 (en) | Modified bacteriophage including an alpha/beta small acid-soluble spore protein (sasp) gene | |
WO2011047148A3 (en) | Electrosurgical plenum | |
UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre | |
WO2009131698A3 (en) | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF | |
WO2011097619A3 (en) | Silica-based composite ocular device and methods |